Trinity Biotech (TRIB) Return on Equity (2009 - 2022)

Trinity Biotech's (TRIB) quarterly Return on Equity came in at 0.19% in Q4 2022, up 92.69% quarter-over-quarter from 2.67% in Q2 2009.

Trinity Biotech (TRIB) Return on Equity (2009 - 2022) Analysis & Trends

Trinity Biotech has disclosed Return on Equity across 2 years of filings, most recently posting 0.19% for Q4 2022.

Return on Equity for Q4 2022 came in at 0.19%, changed N/A year-over-year; the trailing twelve-month figure through Dec 2022 was 0.19% (changed N/A YoY), and the FY2025 annual result was 0.01%, up 1.0% from the prior year.
Return on Equity came in at 0.19% for Q4 2022 at Trinity Biotech, up from 2.67% in the prior quarter.
In the past five years, Return on Equity ranged from a high of 0.19% in Q4 2022 to a low of 0.19% in Q4 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROE (Qtr)
1	Abbott Laboratories	154.42 Bn	147.76 Bn	6.27 Bn	0.00%
2	Stryker	118.12 Bn	115.25 Bn	3.81 Bn	0.00%
3	Medtronic	101.72 Bn	93.55 Bn	5.76 Bn	0.00%
4	Boston Scientific	67.19 Bn	65.98 Bn	3.61 Bn	0.00%
5	Edwards Lifesciences	50.69 Bn	47.02 Bn	1.29 Bn	0.00%
6	Koninklijke Philips	29.38 Bn	26.07 Bn	2.07 Bn	0.00%
7	Dexcom	28.09 Bn	26.97 Bn	750.30 Mn	0.00%
8	GE HealthCare Technologies	28.08 Bn	26.02 Bn	1.98 Bn	0.00%
9	Steris	19.80 Bn	19.37 Bn	697.10 Mn	-
10	Trinity Biotech	23,520.00	-5.11 Mn	-	-

Download Data